Healthcare is increasingly driven by prevention, personalization and data. Nowhere is this more clear than carrier testing, which is an important part of women’s health. An increasing number of people and couples are interested in knowing about their chances of genetic diseases and diseases before the child is conceived, rather than waiting to find out if the child has a certain condition. Because of this, the property inspection market is growing in the United States.
According to IMARC Group, the size of the US carrier testing for genetic diseases market is expected to grow at a compound annual growth rate (CAGR) of 13.87% from 2025 to 2033. It points to growth for healthcare providers who are focusing on providing information about genetic risk to help individuals/couples make decisions about family planning.
Carrier testing can result in the identification of abnormal genes associated with inherited diseases, particularly autosomal recessive conditions. IMARC explains that saliva samples, blood samples, or cheek tissue samples may be required. Carrier testing can assess the genetic risk of passing on cystic fibrosis, sickle cell anemia and Tay-Sachs disease to children. This makes patient assessment relevant to clinical practice, medical genetics, preventive medicine and reproductive health.
Personalized medicine is also a major market driver. According to IMARC, as genetic risk awareness and health care planning grows, so does the number of patients being screened. The bottom line is that the broad perception of what patients want from their health care is that they want tools so they can make decisions sooner rather than later.
New technologies such as DNA sequencing, polymerase chain reaction (PCR)‚ and microarray technologies provide more accurate methods of carrier screening. With increasing accuracy and completeness, technology is becoming more effective in providing part of routine care. This approach is being shown to move from a specific death test to the benefit of broader diagnostic panels.
Another market trend is the increase in awareness among health professionals about expanded carrier testing. As with IMARC, there is a growing trend of diagnostic panels to expand pulmonary, hematological, and neurologic diagnostic criteria. However, the market seems to be expanding in an area where people and couples have a clearer view of the risks that can be caused by genetics before having children and building a family.
Telehealth has also affected this group, while IMARC says that genetic testing is now widely available in the United States thanks to telephone solutions, as adoption is largely influenced by the convenience of testing and counseling, and genetic testing is easily accessible to many people, as it is not limited to specialized centers for residents of central cities when it is ordered remotely. This can be presented in IMARC’s discussion of improved access by telephone.
Segmentation: The IMARC report has segmented the market based on product types into extended patient diagnostics and targeted patient diagnostics. Furthermore, the report has segmented the market based on medical condition into pulmonary conditions, hematological conditions, neurological conditions, and others. In terms of technology, the market is segmented into DNA sequencing, polymerase chain reaction (PCR), microarray‚ and others. Based on end users, the market is segmented into hospitals and clinics, reference laboratories, and others. It is studied regionally in the Northeast, Midwest, South‚ and West.
The interest in some of the carrier screening markets in the United States reflects a broader movement in the health care industry to provide people with information that will help them plan ahead, reduce uncertainty, and approach family life with greater confidence in the unknown. Therefore, from that perspective, patient assessment is not just another form of assessment, but part of a broader approach to individualized health care. This last point is a description of the methods and drivers reported by IMARC.
For readers who want to take a closer look at forecasting methods, analysis models, and technical aspects, the IMARC Group’s comprehensive study provides comprehensive information.
#U.S #Surgery #Market #Growing #Genetic #Prevention #Care